Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Rituximab in Relapsed Indolent B-Cell Non-Hodgkin Lymphoma
NCT01200589Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of ofatumumab in B-cell non-Hodgkin lymphoma, sponsored by Novartis. Started Oct 2010; status: terminated.
02
Drugs
ofatumumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01200589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01200589.